Refine by
775 results found
-
Regulatory Comment to the FDA on Health Equity
Regulatory comment supporting the FDA’s proposed rule banning electrical stimulation devices, and urging the FDA to take all necessary steps to release the final rule as soon as possible. -
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter encouraging Congress to support the funding level proposed by the Senate Appropriations Committee for two NIH programs, the BRAIN Initiative and the All of Us Research Program, which would continue to make revolutionary advances that can improve brain and overall health outcomes. -
Letter to Congressional Leadership on Medicaid and Criminal Justice
Letter urging House and Senate leadership to pass the Reentry Act (H.R.2400/S.1165) and Due Process Continuity of Care Act (H.R.3074/S.971) before the end of the 118th Congress. -
Letter to Congressional Leadership on Due Process Continuity of Care Act and the Re-entry Act
Letter from over 66 organizations representing behavioral health and criminal justice, to Senate and House leadership requesting that they pass the Reentry Act (H.R. 2400/S. 1165) and Due Process Continuity of Care Act (H.R. 3074/S. 971) by the end of the session. -
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter urging Congress to finalize the Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS) spending bill by the end of the calendar year with a robust investment in the NIH. -
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter requesting that Congress include the $5 million for the FDA’s Neurology Drug Program, as proposed by the Senate Appropriations Committee. -
Regulatory Comment to HHS on Health Coverage
Regulatory comment to Secretary Becerra and Administrator Brooks-LaSure in support of the Notice of Benefit and Payment Parameters for 2026 Proposed Rule, and offering comments to strengthen the rule. -
Letter to Congressional Leadership on Mental Health Funding
Letter to House and Senate Leadership urging the passage of full funding for the FY25 Appropriations Package and the reauthorization of the SUPPORT Act, in an end-of-year omnibus. -
Regulatory Comment on Medication Access
Regulatory comment encouraging FDA to remove barriers to care by allowing patients the choice to opt out of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) after the initial highest risk period and to allow for emergency prescriptions when the administrative barriers are not met. -
Letter to Congressional Committee Leadership on Mental Health Funding and Crisis Services
Letter to House and Senate Appropriations Committees in support of robust FY25 funding for the Comprehensive Suicide Prevention Program under the CDC’s National Center for Injury Prevention and Control.